Shaoyue Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Shaoyue Li has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Hui-Xiong Xu
Department of Ultrasound, Institute of Ultrasound in Medicine and Engineering, Zhongshan Hospital, Fudan University, Shanghai, China
4 shared publications Yuting Shen
Department of Ultrasound Zhongshan Hospital Institute of Ultrasound in Medicine and Engineering Fudan University Shanghai P. R. China
4 shared publications- Li-Ping Sun
Department of Medical Ultrasound, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China
3 shared publications Bing Xiong
Department of Ultrasound, Institute of Ultrasound in Medicine and Engineering, Zhongshan Hospital, Fudan University, Shanghai, P. R. China
2 shared publications- Haohao Yin
Department of Ultrasound, Institute of Ultrasound in Medicine and Engineering, Zhongshan Hospital, Fudan University, Shanghai, China
2 shared publications - Jifeng Yu
Department of Ultrasound, Institute of Ultrasound in Medicine and Engineering, Zhongshan Hospital, Fudan University, Shanghai, P. R. China
2 shared publications
Latest Publications
- Open Access
- 28 September 2026
- Published by Wiley in Advanced Science
Targeting Macrophage‐Mediated Lymphatic Immunosuppression to Prevent Tumor Recurrence After Microwave Ablation
Microwave ablation (MWA) is an effective locoregional therapy for solid tumors, but recurrence caused by minimal residual disease remains a clinical challenge. Although immunotherapy offers a strategy to prevent recurrence, the role of tumor‐draining lymph nodes (TDLNs) in post‐ablation immune regulation remains underexplored. Here, single‐cell RNA sequencing (scRNA‐seq) reveals pronounced macrophage remodeling in TDLNs following incomplete MWA (iMWA), characterized by an increased representation of immunosuppressive Folr2 + and Apoe + macrophage subsets. These populations exhibit broad colony‐stimulating factor 1 receptor ( Csf1r ) expression, accompanied by enhanced CSF signaling and macrophage‐centered intercellular communication, implicating CSF1R‐associated macrophage remodeling in post‐ablation immunosuppression. Accordingly, an albumin‐based lipoprotein nanosystem co‐encapsulating paclitaxel (PTX) and the CSF1R inhibitor BLZ945 (PTX/BLZ945@Alb‐lip) was developed. Across multiple tumor models, PTX/BLZ945@Alb‐lip enhances immunomodulator delivery to both TDLNs and tumors, remodels the macrophage‐mediated immunosuppressive microenvironment, and suppresses residual tumor growth after iMWA. Moreover, treatment promotes durable antitumor immune memory and protects cured mice against tumor rechallenge. These findings identify TDLNs as an important therapeutic site in post‐ablation immunotherapy and provide a potential strategy to prevent tumor recurrence following ablation.
- 28 September 2026
- Published by Wiley in Advanced Science
Open AccessTargeting Macrophage‐Mediated Lymphatic Immunosuppression to Prevent Tumor Recurrence After Microwave Ablation
Microwave ablation (MWA) is an effective locoregional therapy for solid tumors, but recurrence caused by minimal residual disease remains a clinical challenge. Although immunotherapy offers a strategy to prevent recurrence, the role of tumor‐draining lymph nodes (TDLNs) in post‐ablation immune regulation remains underexplored. Here, single‐cell RNA sequencing (scRNA‐seq) reveals pronounced macrophage remodeling in TDLNs following incomplete MWA (iMWA), characterized by an increased representation of immunosuppressive Folr2 + and Apoe + macrophage subsets. These populations exhibit broad colony‐stimulating factor 1 receptor ( Csf1r ) expression, accompanied by enhanced CSF signaling and macrophage‐centered intercellular communication, implicating CSF1R‐associated macrophage remodeling in post‐ablation immunosuppression. Accordingly, an albumin‐based lipoprotein nanosystem co‐encapsulating paclitaxel (PTX) and the CSF1R inhibitor BLZ945 (PTX/BLZ945@Alb‐lip) was developed. Across multiple tumor models, PTX/BLZ945@Alb‐lip enhances immunomodulator delivery to both TDLNs and tumors, remodels the macrophage‐mediated immunosuppressive microenvironment, and suppresses residual tumor growth after iMWA. Moreover, treatment promotes durable antitumor immune memory and protects cured mice against tumor rechallenge. These findings identify TDLNs as an important therapeutic site in post‐ablation immunotherapy and provide a potential strategy to prevent tumor recurrence following ablation.
- 27 July 2026
- Published by American Chemical Society (ACS) in ACS Nano Medicine
- Vol. 1 (9) , 2429-2441
Synchronizing Tumor Oxygen Dynamics via 19F-MRI-Guided Nanotheranostics Enables Precision Radiotherapy
The therapeutic efficacy of radiotherapy (RT) is fundamentally constrained by tumor hypoxia, a dynamic and heterogeneous feature of the tumor microenvironment that drives radioresistance and disease progression. Despite advances in oxygen-supplementation strategies, the inability to resolve and exploit temporal oxygen fluctuations limits their clinical impact. Here, we report a fluorine-19 MRI-guided nanotheranostic platform that synchronizes tumor oxygen dynamics with precision radiotherapy. Perfluorocarbon-based nanodroplets function dually as oxygen carriers and quantitative imaging probes, leveraging the linear dependence of the 19F longitudinal relaxation rate (R1) on the oxygen partial pressure (pO2) to enable noninvasive mapping of tumor oxygenation. This approach identifies a transient peak oxygenation window following administration, providing a rational basis for temporally optimized RT delivery. Synchronizing irradiation with this imaging-defined window significantly amplifies reactive oxygen species (ROS) generation and DNA double-strand breaks, resulting in enhanced tumor regression and prolonged survival. Beyond direct radiosensitization, this strategy establishes a paradigm for converting stochastic hypoxia into a controllable therapeutic variable. This work presents a framework for timing-informed, image-guided precision radiotherapy, advancing the frontier of oxygen-modulated cancer therapy.
- 27 July 2026
- Published by American Chemical Society (ACS) in ACS Nano Medicine
- Vol. 1 (9) , 2429-2441
Synchronizing Tumor Oxygen Dynamics via 19F-MRI-Guided Nanotheranostics Enables Precision Radiotherapy
The therapeutic efficacy of radiotherapy (RT) is fundamentally constrained by tumor hypoxia, a dynamic and heterogeneous feature of the tumor microenvironment that drives radioresistance and disease progression. Despite advances in oxygen-supplementation strategies, the inability to resolve and exploit temporal oxygen fluctuations limits their clinical impact. Here, we report a fluorine-19 MRI-guided nanotheranostic platform that synchronizes tumor oxygen dynamics with precision radiotherapy. Perfluorocarbon-based nanodroplets function dually as oxygen carriers and quantitative imaging probes, leveraging the linear dependence of the 19F longitudinal relaxation rate (R1) on the oxygen partial pressure (pO2) to enable noninvasive mapping of tumor oxygenation. This approach identifies a transient peak oxygenation window following administration, providing a rational basis for temporally optimized RT delivery. Synchronizing irradiation with this imaging-defined window significantly amplifies reactive oxygen species (ROS) generation and DNA double-strand breaks, resulting in enhanced tumor regression and prolonged survival. Beyond direct radiosensitization, this strategy establishes a paradigm for converting stochastic hypoxia into a controllable therapeutic variable. This work presents a framework for timing-informed, image-guided precision radiotherapy, advancing the frontier of oxygen-modulated cancer therapy.
- Open Access
- 19 March 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Low-intensity focused ultrasound-activated piezoelectric gel bandage for diabetic wound repair and neuropathic pain relief
Nociceptive hypersensitivity and prolonged wound healing due to the interaction of peripheral neuropathy and local immune disorders are key issues that need to be addressed in diabetic foot ulcer (DFU) regenerative repair. Here, we present a low-intensity focused ultrasound (LIFU)-activated piezoelectric gel bandage for DFU wound repair and neuropathic pain relief. Acting as an artificial “skin”, this self-powered, functionalized bandage not only temporarily shields tissue from external environment, but also serves as a drug reservoir that can in situ release nitric oxide upon LIFU to promote macrophage polarization, generate piezoelectric current to desensitize TRPV1 nociceptor for on demand neuropathic pain relief and produce reactive oxygen species to eliminate pathogens in male rodents. More importantly, this regimen can promote CGRP neuropeptides release from sensory neurons to invigorate M2-like macrophages-mediated protective cutaneous immunity. This LIFU-activated immune-nociceptor modulation strategy is potentially applicable to other non-healing tissue regeneration.
- 19 March 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessLow-intensity focused ultrasound-activated piezoelectric gel bandage for diabetic wound repair and neuropathic pain relief
Nociceptive hypersensitivity and prolonged wound healing due to the interaction of peripheral neuropathy and local immune disorders are key issues that need to be addressed in diabetic foot ulcer (DFU) regenerative repair. Here, we present a low-intensity focused ultrasound (LIFU)-activated piezoelectric gel bandage for DFU wound repair and neuropathic pain relief. Acting as an artificial “skin”, this self-powered, functionalized bandage not only temporarily shields tissue from external environment, but also serves as a drug reservoir that can in situ release nitric oxide upon LIFU to promote macrophage polarization, generate piezoelectric current to desensitize TRPV1 nociceptor for on demand neuropathic pain relief and produce reactive oxygen species to eliminate pathogens in male rodents. More importantly, this regimen can promote CGRP neuropeptides release from sensory neurons to invigorate M2-like macrophages-mediated protective cutaneous immunity. This LIFU-activated immune-nociceptor modulation strategy is potentially applicable to other non-healing tissue regeneration.
- Open Access
- 25 July 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (30) , eadw2937
Targeting tumor-associated CCR2 + macrophages to inhibit pancreatic cancer recurrence following irreversible electroporation
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy with pronounced resistance to conventional therapies. Irreversible electroporation (IRE) is a promising therapy for PDAC; however, its clinical efficacy is limited by a high recurrence rate. Here, using a preclinical PDAC model, we characterized the tumor immune microenvironment following insufficient IRE (iIRE) through single-cell RNA sequencing. We found that iIRE induces a CCR2 + tumor-associated macrophage (CCR2 + TAM)–mediated immunosuppressive microenvironment in residual tumors. Consequently, we developed a macrophage-based proteolipid vesicle (mPLV) coencapsulating the CCR2 antagonist PF-4136309 (PF) and gemcitabine (GEM), named PF/GEM@mPLV. Our findings suggest that PF/GEM@mPLV achieves high drug accumulation within tumors through iIRE-induced inflammation. Reduction of CCR2 + TAMs enhances antitumor immunity and improves chemotherapeutic response. PF/GEM@mPLV markedly inhibits tumor recurrence following iIRE, diminishes hepatic metastases, and prolongs survival in preclinical PDAC models. These findings uncover the role of CCR2 + TAMs in iIRE-induced immunosuppression, offering a promising strategy to enhance the clinical potential of IRE in PDAC.
- 25 July 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (30) , eadw2937
Open AccessTargeting tumor-associated CCR2 + macrophages to inhibit pancreatic cancer recurrence following irreversible electroporation
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy with pronounced resistance to conventional therapies. Irreversible electroporation (IRE) is a promising therapy for PDAC; however, its clinical efficacy is limited by a high recurrence rate. Here, using a preclinical PDAC model, we characterized the tumor immune microenvironment following insufficient IRE (iIRE) through single-cell RNA sequencing. We found that iIRE induces a CCR2 + tumor-associated macrophage (CCR2 + TAM)–mediated immunosuppressive microenvironment in residual tumors. Consequently, we developed a macrophage-based proteolipid vesicle (mPLV) coencapsulating the CCR2 antagonist PF-4136309 (PF) and gemcitabine (GEM), named PF/GEM@mPLV. Our findings suggest that PF/GEM@mPLV achieves high drug accumulation within tumors through iIRE-induced inflammation. Reduction of CCR2 + TAMs enhances antitumor immunity and improves chemotherapeutic response. PF/GEM@mPLV markedly inhibits tumor recurrence following iIRE, diminishes hepatic metastases, and prolongs survival in preclinical PDAC models. These findings uncover the role of CCR2 + TAMs in iIRE-induced immunosuppression, offering a promising strategy to enhance the clinical potential of IRE in PDAC.
- Top Cited PapersOpen Access
- 10 February 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-19
Transdermal microneedle-assisted ultrasound-enhanced CRISPRa system to enable sono-gene therapy for obesity
Obesity, a surging global health challenge, necessitates effective, accessible and innovative therapeutic models. Here we develop a spatiotemporally controllable microneedle (MN) drug delivery platform for sono-gene therapy to fight obesity. The platform delivers the methoxy polyethylene glycol-polyethyleneimine (mPEG-PEI) modified metal-organic frameworks (MOFs) sonosensitizer and the clustered regularly interspaced short palindromic repeats-activating (CRISPRa)/CRISPRa-uncoupling protein 1 (UCP1) system intradermally to adipocytes. Overall, this therapy platform is capable of achieving two major strategies of “annihilation” and “countermeasure”: one is to kill redundant white adipocytes by sonodynamic therapy, and the other is to promote the browning of white adipocytes through the controllable release of CRISPRa-UCP1 system and sonodynamic effect. Obese male mice treated with this sono-gene therapy shows significant ameliorate in glucose tolerance and insulin sensitivity, successfully achieves weight loss and restrains weight rebound. This study may enable a standard treatment paradigm for sono-gene therapy of obesity and other metabolic diseases.
- 10 February 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-19
Top Cited PapersOpen AccessTransdermal microneedle-assisted ultrasound-enhanced CRISPRa system to enable sono-gene therapy for obesity
Obesity, a surging global health challenge, necessitates effective, accessible and innovative therapeutic models. Here we develop a spatiotemporally controllable microneedle (MN) drug delivery platform for sono-gene therapy to fight obesity. The platform delivers the methoxy polyethylene glycol-polyethyleneimine (mPEG-PEI) modified metal-organic frameworks (MOFs) sonosensitizer and the clustered regularly interspaced short palindromic repeats-activating (CRISPRa)/CRISPRa-uncoupling protein 1 (UCP1) system intradermally to adipocytes. Overall, this therapy platform is capable of achieving two major strategies of “annihilation” and “countermeasure”: one is to kill redundant white adipocytes by sonodynamic therapy, and the other is to promote the browning of white adipocytes through the controllable release of CRISPRa-UCP1 system and sonodynamic effect. Obese male mice treated with this sono-gene therapy shows significant ameliorate in glucose tolerance and insulin sensitivity, successfully achieves weight loss and restrains weight rebound. This study may enable a standard treatment paradigm for sono-gene therapy of obesity and other metabolic diseases.